Immunovaccine Vaccinates First Patient with DPX-Survivac
Immunovaccine Inc. has announced that the first patient has been vaccinated with DPX-Survivac, a therapeutic cancer vaccine.
The goal of the Phase I clinical trial is to establish the safety and immune activity of DPX-Survivac in patients with ovarian cancer.
The DPX-Survivac Phase I and II clinical trials have been cleared by both the U.S. FDA and Health Canada.
DPX-Survivac is a survivin-targeting vaccine formulated in the DepoVax™ platform, a patented vaccine delivery and method that is expected to enhance the immunogenicity of the survivin antigen used in DPX-Survivac.
The survivin antigen contained in the vaccine is a broadly expressed, tumor-associated antigen shown to sustain the survival of cancer cells.
In combination with the DepoVax platform, it is expected to stimulate the immune system to destroy cancer cells expressing survivin and delay cancer recurrence.
DPX-Survivac will be administered to patients after debulking surgery and chemotherapy treatments. Vaccinated patients will also receive an immune modulating drug to further enhance the activity of the vaccine.
"We believe this is the right vaccine being administered at the right time," commented Dr. Mansour, Chief Science and Operating Officer.
Dr. Mansour continued, "Applying our DepoVax enhanced vaccine after surgery and chemotherapy is when therapeutic cancer vaccines are expected to be most effective."